BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sinocelltech Group Ltd. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Sinocelltech Group Ltd.'s drugs r
 un\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07538154-3146@assetmemo.bio
DTSTAMP:20261121T005447Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:SCTC21C: Phase 1/2 readout est. (NCT07538154)
DESCRIPTION:SCTC21C\, phase 1/2\, Systemic Lupus Erythematosus.\nStudy: A C
 linica Study of SCTC21C in Participants With Systemic Lupus Erythematosus\
 nEstimated primary completion: April 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/sctc21c#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07538154
URL:https://assetmemo.bio/drug/sctc21c#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06600022-2178@assetmemo.bio
DTSTAMP:20261121T005447Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:SCTB41: Phase 1/2 readout est. (NCT06600022)
DESCRIPTION:SCTB41\, phase 1/2.\nStudy: Aims to Explore the Safety\, Tolera
 bility\, and Preliminary Efficacy of SCTB41 in Adult Patients with Advance
 d Malignant Solid Tumours.\nEstimated primary completion: 30 April 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/sctb41#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06600022
URL:https://assetmemo.bio/drug/sctb41#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07362459-2721@assetmemo.bio
DTSTAMP:20261121T005447Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:SCTB14: Phase 3 readout est. (NCT07362459)
DESCRIPTION:SCTB14\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Study 
 to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in
  Non-Small Cell Lung Cancer.\nEstimated primary completion: July 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/sctb14#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07362459
URL:https://assetmemo.bio/drug/sctb14#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06774664-3146@assetmemo.bio
DTSTAMP:20261121T005447Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:SCTC21C: Phase 1/2 readout est. (NCT06774664)
DESCRIPTION:SCTC21C\, phase 1/2\, IgA Nephropathy.\nStudy: A Clinical Study
  of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases\nE
 stimated primary completion: September 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/sctc21c#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06774664
URL:https://assetmemo.bio/drug/sctc21c#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07297329-3146@assetmemo.bio
DTSTAMP:20261121T005447Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:SCTC21C: Phase 3 readout est. (NCT07297329)
DESCRIPTION:SCTC21C\, phase 3\, Multiple Myeloma.\nStudy: A Study to Evalua
 te the Safety and Efficacy of SCTC21C in Combination With Bortezomib\, Len
 alidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myel
 oma Not Eligible for Transplant\nEstimated primary completion: December 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/sctc21c#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07297329
URL:https://assetmemo.bio/drug/sctc21c#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07388602-3146@assetmemo.bio
DTSTAMP:20261121T005447Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:SCTC21C: Phase 3 readout est. (NCT07388602)
DESCRIPTION:SCTC21C\, phase 3\, AL Amyloidosis.\nStudy: A Study to Evaluate
  the Safety and Efficacy of SCTC21C in Combination With Bortezomib\, Cyclo
 phosphamide\, and Dexamethasone in Patients With Newly Diagnosed Systemic 
 Light-Chain Amyloidosis (NDSLCA)\nEstimated primary completion: December 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/sctc21c#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07388602
URL:https://assetmemo.bio/drug/sctc21c#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06304818-2721@assetmemo.bio
DTSTAMP:20261121T005447Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:SCTB14: Phase 1/2 readout est. (NCT06304818)
DESCRIPTION:SCTB14\, phase 1/2.\nStudy: Aims to Explore the Safety\, Tolera
 bility\, and Preliminary Efficacy of SCTB14 in Adult Patients With Advance
 d Malignant Solid Tumours.\nEstimated primary completion: 30 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/sctb14#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06304818
URL:https://assetmemo.bio/drug/sctb14#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07819188-2178@assetmemo.bio
DTSTAMP:20261121T005447Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:SCTB41: Phase 1/2 readout est. (NCT07819188)
DESCRIPTION:SCTB41\, phase 1/2.\nStudy: SCTB35 and SCTB41 With or Without C
 hemotherapy in Non-Hodgkin Lymphoma\nEstimated primary completion: 30 Sept
 ember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sctb41#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078191
 88
URL:https://assetmemo.bio/drug/sctb41#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07609251-2178@assetmemo.bio
DTSTAMP:20261121T005447Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:SCTB41: Phase 2 readout est. (NCT07609251)
DESCRIPTION:SCTB41\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Clinic
 al Study of SCTB41 Combined With Docetaxel in Patients With Previously Tre
 ated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II 
 Study Ongoing）\nEstimated primary completion: October 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/sctb41#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07609251
URL:https://assetmemo.bio/drug/sctb41#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07594028-2178@assetmemo.bio
DTSTAMP:20261121T005447Z
DTSTART;VALUE=DATE:20290530
DTEND;VALUE=DATE:20290531
SUMMARY:SCTB41: Phase 1/2 readout est. (NCT07594028)
DESCRIPTION:SCTB41\, phase 1/2.\nStudy: Phase I/II Study of SCTB41 Plus SCT
 B39-1with or Without Standard Therapy in Advanced Solid Tumours\nEstimated
  primary completion: 30 May 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/sctb41#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07594028
URL:https://assetmemo.bio/drug/sctb41#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07665970-2178@assetmemo.bio
DTSTAMP:20261121T005447Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:SCTB41: Phase 1/2 readout est. (NCT07665970)
DESCRIPTION:SCTB41\, phase 1/2.\nStudy: SCTB41 Plus SCTB39G With or Without
  Standard Therapy in Advanced Solid Tumors\nEstimated primary completion: 
 30 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sctb41#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0766
 5970
URL:https://assetmemo.bio/drug/sctb41#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662395-2178@assetmemo.bio
DTSTAMP:20261121T005447Z
DTSTART;VALUE=DATE:20300124
DTEND;VALUE=DATE:20300125
SUMMARY:SCTB41: Phase 2/3 readout est. (NCT07662395)
DESCRIPTION:SCTB41\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: SCTB41
  Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cance
 r\nEstimated primary completion: 24 January 2030. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/sctb41#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07662395
URL:https://assetmemo.bio/drug/sctb41#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
